Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2019 December;71(6) > Minerva Ginecologica 2019 December;71(6):434-41

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

Minerva Ginecologica 2019 December;71(6):434-41

DOI: 10.23736/S0026-4784.19.04466-6

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Prevention of vaginal dryness in perimenopausal women. Supplementation with Lady Prelox®

Maria R. CESARONE 1, 2, Gianni BELCARO 1, 2 , Claudia SCIPIONE 1, 2, Valeria SCIPIONE 1, 2, Mark DUGALL 1, 2, Shu HU 3, Roberto COTELLESE 3, Beatrice FERAGALLI 1, 2, Andrea LEDDA 1, 2

1 IRVINE3 Labs & Pap/Pea Screening Project and the International Irvine Network, Pescara, Italy; 2 IAAPS, International Agency for Pharma Standard Supplements, Chieti, Italy; 3 Department of Medical, Oral Sciences and Biotechnologies, G. D’Annunzio University, Pescara, Italy



BACKGROUND: The aim of this pilot registry study was to use a standardized supplement (Lady Prelox®, Horphag Research) - including Pycnogenol®, l-arginine, L-citrulline and rose hip extract - to improve signs and symptoms associated with vaginal dryness in pre and post-menopausal healthy women. A group of women used only a standard management (SM) and a second group added Lady Prelox®.
METHODS: Four groups of women were included in the study. 34 pre-menopausal and 38 post-menopausal women took Lady Prelox®, four tablets daily for 8 weeks and 33 pre-menopausal women and 35 post-menopausal women served as controls.
RESULTS: No safety problems were observed with the supplement that was well tolerated. The subgroups of controls and supplemented subjects were comparable in both the pre- and post-menopausal groups. Among pre-menopausal women, results of the female sexual function index (FSFI) were significantly improved with the supplement in comparison with the control subjects’ group (P<0.05). The results of the FSFI questionnaire for post-menopausal women indicated a significant improvement at 8 weeks with Lady Prelox® (P<0.05) in comparison with controls. Preclinical items (vaginal dryness, pain/discomfort during intercourse, mucus, minimal infections, presence of candida and oxidative stress) were significantly improved (P<0.05) with Lady Prelox®) in comparison to minimal changes with the SM group. These measurements included all women.
CONCLUSIONS: The effects of the supplementation with Lady Prelox® on vaginal dryness were significant. The supplement was well accepted and revealed no side effects or tolerability problems. Further studies are evaluating the effects of Lady Prelox® on other aspects of the menopausal transition that may alter the quality of life of most women in advanced age. A gentle approach with suitable dietary supplementation, represents a promising option for addressing common challenges that women experience in such conditions.


KEY WORDS: Surveys and questionnaires; Dietary supplements; Coitus; Menopause; Pycnogenols; Sexual health

top of page